{"doi":"10.1002/mus.27540","title":"MUS MGFA Abstracts","abstract":"Introduction: The 26-week, phase 3, randomized, double-blind, placebo-controlled CHAMPION MG study (NCT03920293) demonstrated the efficacy and tolerability of the terminal complement C5 inhibitor ravulizumab, administered every 8 weeks, in patients with anti-acetylcholine receptor antibody-positive (AChR Ab+) generalized myasthenia gravis (gMG).A post hoc analysis was performed of responses according to time from MG diagnosis.Methods: Enrolled patients with Myasthenia Gravis-Activities of Daily Living (MG-ADL) or Quantitative Myasthenia Gravis (QMG) assessments at baseline and Week 26 were included in the analyses.Mean changes from baseline to Week 26 in MG-ADL and QMG total scores were assessed in ravulizumab-and placebo-treated patient subgroups according to time from MG diagnosis to study start (date of informed consent).Results: Analyses of MG-ADL and QMG scores included 160 and 154 patients, respectively.Mean (standard deviation) changes from baseline to Week 26 in MG-ADL total score by time from diagnosis (2, >2-5, >5-10, >10 years) for ravulizumab were -4.6 (3.6), -3.5(3.0), -2.3 (3.6), -2.9 (2.8), respectively; and for placebo were -1.7 (3.4), -1.8 (3.0), -0.8 (4.0), -1.6 (2.6), respectively.Corresponding data for QMG total score in ravulizumab-and placebo-treated patient subgroups showed similar patterns of response. Conclusion: A trend was observed toward greater reduction from baseline to Week 26 in MG-ADL and QMG total scores in patients with AChR Ab+ gMG who initiated ravulizumab earlier after MG diagnosis compared with later.The placebo group did not demonstrate a similar trend.Potential benefits of ravulizumab administration early after MG diagnosis warrant further investigation.","journal":"Muscle & Nerve","year":2022,"id":294872,"datarank":0.0,"base_score":0.0,"endowment":0.0,"self_citation_contribution":0.0,"citation_network_contribution":0.0,"self_endowment_contribution":0.0,"citer_contribution":0.0,"corpus_percentile":null,"corpus_rank":null,"citation_count":2,"citer_count":0,"citers_with_citation_signal":0,"citers_with_endowment":0,"datacite_reuse_total":0,"is_dataset":false,"is_dataset_confidence":0.7476,"is_data_producer":false,"deposit_databanks":null,"is_oa":true,"file_count":0,"downloads":0,"has_version_chain":false,"published_date":"2022-01-01","fair_score":null,"fair_percentile":null,"algorithm_id":"datarank_citation_only_1hop_v6","ranking_scope":"data_only","authors":[{"id":980933,"name":"phase 3","orcid":null,"position":1,"is_corresponding":false},{"id":980934,"name":"randomized","orcid":null,"position":2,"is_corresponding":false},{"id":980935,"name":"double-blind","orcid":null,"position":3,"is_corresponding":false},{"id":980936,"name":"placebo-controlled CHAMPION MG study (NCT03920293) demonstrated the efficacy and tolerability of the terminal complement C5 inhibitor ravulizumab","orcid":null,"position":4,"is_corresponding":false},{"id":980937,"name":"administered every 8 weeks","orcid":null,"position":5,"is_corresponding":false},{"id":980938,"name":"in patients with anti-acetylcholine receptor antibody-positive (AChR Ab+) generalized myasthenia gravis (gMG). A post hoc analysis was performed of responses according to time from MG diagnosis.","orcid":null,"position":6,"is_corresponding":false},{"id":980932,"name":"The 26-week","orcid":null,"position":0,"is_corresponding":true}],"reference_count":0,"raw_metadata":null,"created_at":"2026-07-19T00:31:05.260069Z","pmid":null,"pmcid":null,"fwci":null,"citation_percentile":null,"influential_citations":0,"oa_status":null,"license":null,"views":0,"total_file_size_bytes":0,"version_count":0,"fair_f":null,"fair_a":null,"fair_i":null,"fair_r":null,"fair_zscore":null,"fair_rationale":null,"fair_model":null,"fair_agent_version":null,"fair_fulltext_source":null,"fair_has_llm":null,"fair_computed_at":null,"clinical_trials":[],"software_tools":[],"db_accessions":[],"linked_datasets":[],"topics":[]}